https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-rp-staging.hbrsd.com/media/dydjvcpi/adobestock_526526544.jpg
Ophthalmology Management
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-rp-staging.hbrsd.com/media/wtedfbg1/rp0926_retinasociety_digital_cover_v1.jpg
Retinal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-rp-staging.hbrsd.com/media/0eypbm5l/0926_fc_gp.jpg
Glaucoma Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-rp-staging.hbrsd.com/media/0jsmmz3o/op_1025_cover_final.jpg
Ophthalmic Professional
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-rp-staging.hbrsd.com/media/12fbjpho/oasc_0726_cover_large.jpg
The Ophthalmic ASC
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-rp-staging.hbrsd.com/media/aqbjxwjw/pp-cover.jpg
Presbyopia Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-rp-staging.hbrsd.com/media/npjdtl1w/cp_november_cover.jpg
Corneal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-rp-staging.hbrsd.com/media/mvqdq2hc/nrp_cover_october_2024.jpg
New Retinal Physician
Thursday, September 24, 2026
At 52 weeks, both doses of remigromig independently demonstrated noninferiority to active control 0.5 mg ranibizumab for mean change from baseline in best-corrected visual acuity in patients with DME.
Wednesday, September 23, 2026
SZN-8141 combines Wnt pathway activation and VEGF inhibition in a single investigational antibody. The company hopes to begin a phase 1b/2a trial later this year.
Wednesday, September 23, 2026
The FDA-approved formulation requires no reconstitution and is now available in the US for ophthalmic angiography.
Monday, September 21, 2026
Beacon plans regulatory discussions after its pivotal VISTA trial showed significant gains in low-luminance visual acuity.
Wednesday, September 16, 2026
The 2026 António Champalimaud Vision Award recognizes their work advancing optogenetics and other approaches to vision restoration.
Wednesday, September 16, 2026
Rolling IND review and earlier site planning could reduce delays before first-in-human studies begin.
Wednesday, September 16, 2026
Ocular Therapeutix plans an NDA submission in the fourth quarter of 2026, based on SOL-1 data and confirmatory evidence.
Friday, September 11, 2026
Low-dose OPGx-BEST1 was associated with functional improvements in all 5 participants in a phase 1/2 trial.
Wednesday, September 9, 2026
Nanoscope’s intravitreal optogenetic therapy targets patients with severe vision loss regardless of the underlying mutation.
By Jim Gallagher, senior managing editor
Tuesday, September 8, 2026
The agreement gives Kala exclusive US distribution rights for Virotek’s ophthalmology genomic testing and screening program.
Tuesday, September 8, 2026
The 180-patient phase 2 study will assess BGE-102 alone and as an adjunct to intravitreal anti-VEGF treatment.
Tuesday, September 8, 2026
The deal brings ALK-001, now in the NORTHSTAR phase 3 trial for Stargardt disease, into Tarsus’s pipeline.
Tuesday, September 8, 2026
The microscope combines advanced optics, novel illumination, improved ergonomics, and intuitive usability in a modular design.
Tuesday, September 1, 2026
The global study will evaluate a single subretinal administration of the investigational gene therapy in geographic atrophy.
Tuesday, September 1, 2026
SALWEEN results found patients gained 7.3 letters of vision, and 74% had no retinal fluid at year 2.
Monday, August 24, 2026
According to Harrow, patients reported approximately 58% less discomfort overall in the Iheezo-treated eye than in the fellow eye treated with proparacaine ophthalmic solution 0.5%.
Monday, August 24, 2026
The phase 3 trial will assess visual outcomes at month 3 in patients with acute-onset optic neuritis.
Monday, August 24, 2026
The phase 3 trial is designed to demonstrate superiority and includes an individualized dosing arm with intervals of up to 24 weeks.
Thursday, August 20, 2026
The software solution combines information from diagnostic devices, electronic medical records, and practice systems, into a comprehensive patient record.
Tuesday, August 18, 2026
The phase 1 trial will assess the safety, pharmacokinetics, and preliminary efficacy of intravitreal RAG-1C in patients undergoing retinal detachment surgery who are at high risk for PVR.
Tuesday, August 18, 2026
The first-in-human study will assess EYC-0305, an investigational anti-VEGF therapy administered at 24-week intervals.
Monday, August 17, 2026
The vorolanib intravitreal insert reduced treatment burden despite failing to achieve noninferiority in the full analysis.
Friday, August 14, 2026
The addition of a Month 24 dual primary endpoint will complement the current Month 15 primary endpoint in its phase 3 ARCHER II trial, the company said.
Thursday, August 13, 2026
Sumitomo Pharma’s DSP-3077 consists of multilayered retinal tissue containing photoreceptor precursors derived from allogeneic induced pluripotent stem cells.
Thursday, August 13, 2026
The FDA set a February 12, 2027, PDUFA date for the investigational oral therapy for Stargardt disease type 1.
Monday, August 10, 2026
The $3.8 million agreement would replace Oculis’s existing license with Accure and transfer worldwide development and commercial rights to Oculis.
Friday, August 7, 2026
The acquisition of Alkeus adds an investigational Stargardt therapy to Tarsus Pharmaceuticals’ retina pipeline.
Friday, August 7, 2026
An independent study presented at the American Retina Forum meeting found immediate improvements in near visual acuity with the Eye6 device in patients with advanced retinal disease.
Wednesday, August 5, 2026
The phase 2 study is evaluating oruvestat in patients with moderate-to-severe nonproliferative diabetic retinopathy.
Tuesday, August 4, 2026
Yesafili (aflibercept-jbvf) is now available in the United States as an FDA-approved interchangeable biosimilar to Regeneron's Eylea.
Tuesday, August 4, 2026
The company expects to initiate dosing of OPGx-LCA5 in the fourth quarter of 2026, with topline data expected by the end of 2027.
Tuesday, August 4, 2026
Clinical trial data showed restoration of functional central vision in many patients with geographic atrophy secondary to AMD.
Friday, July 31, 2026
More than 480 patients with diabetic macular edema have been enrolled in the phase 3 trials evaluating Duravyu. Topline results are expected in late 2027.
Wednesday, July 29, 2026
The $340 million deal would add established retinal laser and diagnostic technologies to the Massachusetts company’s medical business.
Friday, July 24, 2026
Lytenava (Outlook Therapeutics) becomes the first ophthalmic formulation of bevacizumab approved specifically for intravitreal use in the United States.
Friday, July 24, 2026
The i-SIGHT2 trial will assess the safety and effectiveness of an investigational office-based treatment for intermediate dry AMD.
Friday, July 24, 2026
The new Centre of Excellence in India will provide vitreoretinal surgery training through hands-on instruction and virtual education.
Monday, July 13, 2026
CPD100 is a first-in-class hypoxia-targeted therapeutic in neovascular or wet AMD
Friday, July 10, 2026
The FDA has recalled 2,530,182 bottles of eye drops nationwide from India-based Lupin Limited due to the presence of a foreign substance.
Thursday, July 2, 2026
According to ISS National Laboratory, the research sponsor for the project, artificial retinas produced in microgravity show markedly improved uniformity, optical performance, and reproducibility compared to those made on Earth.
Thursday, July 2, 2026
The ranibizumab biosimilar is indicated for wet AMD, RVO-associated macular edema, and myopic choroidal neovascularization.
Monday, June 29, 2026
The FDA 510(k)-cleared laser indirect ophthalmoscope features a fully wireless headset and footswitch.
Monday, June 29, 2026
The phase 3 trial is evaluating gene therapy candidate 4D-150 against aflibercept in neovascular age-related macular degeneration. Topline results are expected in 2027.
Monday, June 29, 2026
The phase 2b/3 NAAVIGATE study is evaluating suprachoroidal sura-vec in nonproliferative diabetic retinopathy.
Thursday, June 25, 2026
The company highlights global use of its ultra-widefield imaging technology.
Tuesday, June 23, 2026
The FDA submission follows positive phase 3 data in Stargardt disease. If approved, tinlarebant could become the first treatment for Stargardt disease type 1.
Tuesday, June 23, 2026
Enrollment is underway in the phase 3 trial of ATSN-201 for XLRS. Topline results are expected in the first half of 2028.
Tuesday, June 23, 2026
If approved, Lytenava would become the first FDA-approved ophthalmic formulation of bevacizumab for retinal disease.
Tuesday, June 23, 2026
The $300 million deal adds PER-001, an investigational intravitreal implant for glaucoma and diabetic retinopathy, to Bayer's pipeline.
Wednesday, June 17, 2026
The company says it is aligned with the FDA on a nAMD submission based on SOL-1 efficacy and safety data, supplemented by interim safety findings from SOL-R.
Tuesday, June 9, 2026
New software cleared recently by the FDA introduces 250 kHz scan speed and Green Autofluorescence imaging to support retinal diagnostics.
Tuesday, June 9, 2026
Alkeus's NORTHSTAR trial will evaluate lesion growth and low-luminance visual acuity in patients with advanced Stargardt disease.
Monday, June 8, 2026
The agency issues draft guidance outlining how sponsors can leverage existing scientific and regulatory knowledge to reduce redundancy and accelerate product development.
Friday, June 5, 2026
The FDA approval of ranibizumab-hkdz adds another interchangeable anti-VEGF option for retinal specialists.
Tuesday, June 2, 2026
Aura Biosciences completes enrollment in the registration-enabling CoMpass study of bel-sar for early choroidal melanoma, with topline data expected in 2027.
Monday, June 1, 2026
The safety and biologic activity of Therini Bio’s anti-fibrin antibody THN391 will be evaluated in a phase 1b study for diabetic macular edema.
Monday, June 1, 2026
Oculis reported retinal thickness reductions but no significant visual acuity benefit after 52 weeks of treatment in the DIAMOND trials.
Wednesday, May 27, 2026
Opti-GAIN investigators reported no significant safety concerns and advanced the gene therapy study to Cohort 2.
Wednesday, May 27, 2026
The company has partnered with InspiroGene to support distribution and patient services ahead of potential FDA approval.
Wednesday, May 27, 2026
The agency determined that clinical data support the effectiveness of Lytenava in wet AMD.
Tuesday, May 19, 2026
The acquisition expands Lexitas’s retina clinical trial, imaging, and surgical innovation capabilities.
Tuesday, May 19, 2026
The company’s PreserVision AREDS3 supplement combines AREDS2 nutrients with a proprietary B-vitamin complex intended to support macular health earlier in AMD.
Monday, May 18, 2026
Orbis International has partnered with Siloam Vision to become the first in the world to use assistive artificial intelligence to support clinicians in screening infants for retinopathy of prematurity.
Wednesday, May 13, 2026
The new assay aims to improve longitudinal monitoring and assess disease dynamics over time.
Monday, May 11, 2026
ARVO presentations highlighted 12-month XLRS results and 3-year outcomes in LCA1.
Monday, May 11, 2026
Clinical and preclinical results presented at ARVO 2026 included updates from the company’s LCA5, BEST1, and RHO programs.
Monday, May 11, 2026
First-in-human trial of PST-611 showed favorable safety findings and early signals of activity in geographic atrophy.
Thursday, May 7, 2026
Oculis will advance Privosegtor, a potential neuroprotective therapy for optic neuritis, into phase 3 testing.
Wednesday, May 6, 2026
The acquisition of Perfuse Therapeutics expands Bayer’s pipeline in ischemia-driven retinal disease and diabetic retinopathy.
Tuesday, May 5, 2026
As part of the RDEP program, the FDA will work closely with Opus Genetics to guide the ongoing development of OPGx-LCA5.
Monday, May 4, 2026
Phase 1/2a data suggest sustained visual and structural effects after single subretinal delivery.
Monday, May 4, 2026
At the Retinal Therapeutics Innovation Summit, Atsena Therapeutics reported consistent functional and structural responses with ATSN-201.
Tuesday, April 28, 2026
The inaugural meeting will bring together clinicians, industry leaders, and developers to explore clinical applications of artificial intelligence.
Tuesday, April 28, 2026
Agent Claire aims to streamline reporting and improve compliance for IRIS Registry users.
Thursday, April 23, 2026
The DIAMOND program evaluates OCS-01, a topical dexamethasone therapy, for diabetic macular edema
Thursday, April 23, 2026
PulseSight will present first-in-human data on its transferrin-based therapy for geography atrophy at the 2026 ARVO meeting in Denver.
Tuesday, April 21, 2026
Company plans regulatory filings following phase 3 data showing functional vision gains.
Tuesday, April 14, 2026
Additional analyses presented at the Vit-Buckle Society meeting underscore durability and prolonged time to retinal thickening, the company reported.
Friday, April 10, 2026
The primary endpoint is mean change in BCVA from baseline to Year 1 in the study eye, using standardized Early Treatment of Diabetic Retinopathy Study vision.
Friday, April 10, 2026
The study assessed the efficacy and safety of Iluvien as baseline therapy in diabetic macular edema.
Friday, April 10, 2026
The updated label allows treatment of RVO-related macular edema beyond 6 months.
Wednesday, April 8, 2026
Bausch+Lomb’s Bi-Blade+ and Adaptive Fluidics aim to improve vitreous removal efficiency and intraoperative pressure control.
Thursday, April 2, 2026
The updated label allows dosing every 20 weeks, the longest FDA-approved interval for any injectable anti-VEGF.
Wednesday, April 1, 2026
The FDA has granted IDE approval allowing US participation in a global study evaluating a noninvasive bioelectric stimulation approach for geographic atrophy.
Wednesday, April 1, 2026
Data from the phase 2/3 GARDian3 trial of OCU410ST are expected later this year.
Tuesday, March 31, 2026
The deal expands Biogen’s portfolio across retina, immunology, and rare disease through the addition of Syfovre and Empaveli.
Friday, March 27, 2026
The investigational therapy uses allogeneic retinal sheets to address progressive vision loss in retinitis pigmentosa.
Friday, March 27, 2026
Phase 3 results showed that Kodiak’s tarcocimab tedromer (Zenkuda) improved diabetic retinopathy severity and lowered progression risk with extended dosing intervals.
Friday, March 27, 2026
The GOLDEN GATE trial will assess a prosthetic capsular bag designed to facilitate secondary IOL fixation in eyes with compromised or absent capsule support.
Thursday, March 26, 2026
The phase 1/2 Opti-GAIN study will assess safety and preliminary efficacy in patients with geographic atrophy.
Tuesday, March 24, 2026
The smart glasses integrate an AI assistant to enhance independence for people with vision loss.
Tuesday, March 24, 2026
After positive 12-month results from the ArMaDa trial, Ocugen plans a registrational phase 3 study of its investigational gene therapy.
Monday, March 23, 2026
A recent study finds the Multi-Luminance Shape Discrimination Test correlates with visual acuity, visual fields, and patient-reported outcomes.
Wednesday, March 18, 2026
Early data in treatment-naïve nAMD show visual gains and favorable pharmacokinetics.
Tuesday, March 10, 2026
Data from a phase 2a study in China suggest visual acuity gains and potential treatment durability.
Tuesday, March 3, 2026
During a symposium, investigators presented findings from the phase 3 SOL-1 trial highlighting the intravitreal insert’s durability and improved visual outcomes in patients with nAMD.
Monday, March 2, 2026
COMO and CAPRI will evaluate the intravitreal vorolanib insert vs the standard of care in treatment-naïve and previously treated patients with diabetic macular edema.
Monday, March 2, 2026
Early functional and anatomical gains observed at 3 months in the first adult patient treated with the subretinal gene therapy.
Thursday, February 19, 2026
As part of its ongoing ROP Education and Support Initiative, Prevent Blindness has declared the third annual Retinopathy of Prematurity (ROP) Awareness Week, Feb. 23 to March 1.
Wednesday, February 18, 2026
The deal adds ERG-focused retinal diagnostics to Ametek's portfolio.
Wednesday, February 11, 2026
The AI-driven 3D model maps polarity changes relevant to AMD progression, which could guide future therapeutic approaches.
Tuesday, February 10, 2026
The phase 3 4FRONT-1 study compares 4D-150, an investigational gene therapy, against aflibercept 2 mg in treatment-naïve patients.
Friday, February 6, 2026
The agreement grants MeiraGTx exclusive rights to ZipBio’s complement-targeting therapies for geographic atrophy.
Tuesday, February 3, 2026
The Aeye-DS device uses AI to allow non-ophthalmic providers to capture retinal images and screen for diabetic retinopathy.
Tuesday, February 3, 2026
Artevo 750 and 850 integrate digital and optical visualization for ophthalmic surgery.
Wednesday, January 28, 2026
The Abu Dhabi–based study will evaluate an investigational AAV therapy for MERTK-related retinitis pigmentosa.
Monday, January 26, 2026
NOV05, a topical tacrolimus ophthalmic solution, is set to enter a phase 2 trial in patients with noninfectious anterior uveitis.
Monday, January 26, 2026
The investigational cell therapy from Bayer AG/BlueRock Therapeutics is being studied for inherited photoreceptor diseases, including retinitis pigmentosa.
Thursday, January 22, 2026
The French company’s PST-611, which is being evaluated in a phase 1 trial, targets iron dysregulation in dry AMD and geographic atrophy.
Tuesday, January 20, 2026
Sakigake designation supports expedited review; FDA, EMA, and Japan conditionally approve the brand name Mogenry for Nanoscope’s optogenetic therapy.
Tuesday, January 20, 2026
Interim ArMaDa data show a reduction in lesion growth with no serious safety signals reported for Ocugen's investigational gene therapy.
Friday, January 16, 2026
The phase 1/2 trial is evaluating a dual-AAV gene therapy for Usher syndrome type 1B.
Tuesday, January 13, 2026
The companies will collaborate on home monitoring and connected care for chronic retinal disease.
Thursday, January 8, 2026
The next-generation VEGF/Ang2 bispecific antibody demonstrates rapid retinal drying and vision gains in patients with diabetic macular edema.
Thursday, January 8, 2026
Complement Therapeutics’s CTx001, an investigational gene therapy that targets complement pathways in geographic atrophy, will be evaluated in a phase 1/2 trial in 2026.
Wednesday, January 7, 2026
The patent extends US intellectual property protection for Nanoscope’s multicharacteristic opsin (MCO) platform through at least 2039.
Tuesday, January 6, 2026
The partnership with VectorBuilder aims to advance IKAR-003, an intravitreal gene therapy designed to slow AMD progression.
Tuesday, January 6, 2026
In a phase 2 trial, the drug showed functional and structural signals in optic neuritis.
Friday, January 2, 2026
Ranibizumab-leyk (Nufymco) is approved for for wet AMD, DME, DR, RVO-related macular edema, and myopic CNV.
Friday, January 2, 2026
The agency says Outlook Therapeutics must provide additional evidence confirming the efficacy of its intravitreal bevacizumab formulation for wet AMD.
Friday, January 2, 2026
Results underscore the potential of alternate objective measures in the pediatric population.
Affiliations:
Specialties:
Areas of Expertise: